20:53:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-20 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-20 Ordinarie utdelning MODTX 0.00 SEK
2024-05-17 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning MODTX 0.00 SEK
2023-05-11 Årsstämma 2023
2023-05-09 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-12 Ordinarie utdelning MODTX 0.00 SEK
2022-05-11 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Modus Therapeutics är verksamt inom bioteknik. Produktportföljen är bred och inkluderar exempelvis sevuparin. Bolagets fokus är att utveckla sevuparin för patienter med sepsis / septisk chock, ett allvarligt och ofta dödligt tillstånd. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten med tillhörande forskning drivs med störst närvaro inom Sverige.
2023-11-14 10:30:00

THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SWITZERLAND, SINGAPORE, UNITED KINGDOM, THE UNITED STATES, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN MODUS THERAPEUTICS HOLDING AB. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW.

The Board of Directors of Modus Therapeutics Holding AB ("Modus" or the "Company") has, in connection with the rights issue with pre-emptive rights for existing shareholders announced on November 8, 2023 (the “Rights Issue"), prepared an EU Growth Prospectus (the “Prospectus") which today has been approved and registered by the Swedish Financial Supervisory Authority.

Publication of Prospectus
The Prospectus has been prepared in connection with the Rights Issue and has today, on November 14, 2023, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and instructions, as well as subscription forms, is available on the Company's website (www.modustx.com) and on the website of Erik Penser Bank (www.penser.se). The Prospectus will also be available on the website of the Swedish Financial Supervisory Authority (www.fi.se).

Summary of the Rights Issue

  • Shareholders in Modus will receive one (1) subscription right per share held on the record date of November 15, 2023
  • Four (4) subscription rights entitle the holder to subscribe for five (5) new shares
  • The subscription price is SEK 2.00 per share
  • Trading in subscription rights will take place during the period from November 17 – November 28, 2023
  • The subscription period runs from November 17 – December 1, 2023

The Rights Issue is covered by subscription commitments of approximately 43.8 percent. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 40.3 million. For further information about the Rights Issue, please refer to the published Prospectus.

Advisors
Erik Penser Bank AB is the financial advisor to Modus in connection with the Issues, and Advokatfirman Vinge KB is the legal advisor.